Published in J Exp Med on June 06, 2005
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 3.15
Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog (2010) 2.91
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
Viral sequence evolution in acute hepatitis C virus infection. J Virol (2007) 2.13
Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89
Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis (2008) 1.79
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis (2010) 1.75
Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med (2005) 1.69
Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. Nat Med (2013) 1.65
Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol (2006) 1.54
Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J Virol (2006) 1.52
The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol Biol (2011) 1.46
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest (2009) 1.46
Immune activation promotes evolutionary conservation of T-cell epitopes in HIV-1. PLoS Biol (2013) 1.44
Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med (2012) 1.43
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 1.35
Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut (2005) 1.33
Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol (2008) 1.28
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J Immunol (2008) 1.28
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog (2008) 1.24
Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol (2007) 1.21
Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol (2010) 1.18
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16
Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16
Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15
Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreak. Hepatology (2011) 1.14
Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol (2008) 1.14
Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A (2013) 1.10
Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res (2010) 1.10
Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J Virol (2008) 1.08
Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol (2008) 1.05
Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology (2010) 1.03
T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect (2013) 1.00
Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol (2007) 0.99
Maternal neutralizing antibody and transmission of hepatitis C virus to infants. J Infect Dis (2008) 0.97
Immunoglobulin allotypes influence IgG antibody responses to hepatitis C virus envelope proteins E1 and E2. Hum Immunol (2008) 0.97
Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther (2013) 0.96
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol J (2008) 0.95
Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin Exp Immunol (2011) 0.94
Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution. J Virol (2007) 0.94
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
A new insight into hepatitis C vaccine development. J Biomed Biotechnol (2010) 0.94
Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8⁺ T cells in early viral evolution. J Virol (2011) 0.93
Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat (2008) 0.92
Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol (2008) 0.92
Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol (2009) 0.92
T cell sensitivity and the outcome of viral infection. Clin Exp Immunol (2009) 0.92
HIV and co-infections. Immunol Rev (2013) 0.92
Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. Hepatology (2011) 0.91
Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection. J Immunol (2012) 0.91
HCV-HIV coinfection: simple messages from a complex disease. PLoS Med (2007) 0.91
The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One (2009) 0.91
Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection. J Gen Virol (2010) 0.89
CD4+ primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells. PLoS One (2014) 0.87
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitope. J Virol (2011) 0.86
Distinctive pattern of sequence polymorphism in the NS3 protein of hepatitis C virus type 1b reflects conflicting evolutionary pressures. J Gen Virol (2008) 0.86
Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. J Virol (2015) 0.86
Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS One (2011) 0.86
Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection. J Virol (2015) 0.86
Adaptive immune response during hepatitis C virus infection. World J Gastroenterol (2014) 0.85
Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure. J Virol (2012) 0.85
Hepatitis C virus: current concepts and future challenges. QJM (2011) 0.85
Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome. J Virol (2012) 0.85
Immunity and hepatitis C: a review. Curr HIV/AIDS Rep (2013) 0.85
CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus. J Infect Dis (2015) 0.83
CD8(+) T-Cell Responses in Acute Hepatitis C Virus Infection. Front Immunol (2014) 0.83
Natural epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte activity. World J Gastroenterol (2010) 0.82
T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antiviral Res (2014) 0.82
Hepatitis C virus adaptation to T-cell immune pressure. ScientificWorldJournal (2013) 0.82
Conflicting selection pressures target the NS3 protein in hepatitis C virus genotypes 1a and 1b. Virus Res (2009) 0.81
Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections. Med Microbiol Immunol (2014) 0.80
A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. J Virol (2016) 0.80
Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine. Immunogenetics (2007) 0.79
Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells. J Virol (2014) 0.79
Update on hepatitis C virus-specific immunity. Curr Opin HIV AIDS (2011) 0.78
Antiviral antibodies are necessary to prevent cytotoxic T-lymphocyte escape in mice infected with a coronavirus. J Virol (2007) 0.78
Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C. J Virol (2013) 0.78
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Transmission and evolution of hepatitis C virus in HCV seroconverters in HIV infected subjects. Virology (2013) 0.77
Cross reactive cellular immune response to HCV genotype 1 and 4 antigens among genotype 4 exposed subjects. PLoS One (2014) 0.77
Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol (2013) 0.76
Estimate of within population incremental selection through branch imbalance in lineage trees. Nucleic Acids Res (2015) 0.76
Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing. J Virol (2015) 0.76
CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3. AIDS (2016) 0.75
Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep (2016) 0.75
Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important? Infect Agent Cancer (2016) 0.75
Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design. PLoS Pathog (2016) 0.75
Cellular immune responses against persistent hepatitis C virus: gone but not forgotten. Gut (2006) 0.75
MODELTEST: testing the model of DNA substitution. Bioinformatics (1998) 101.19
Multiple sequence alignment with Clustal X. Trends Biochem Sci (1998) 15.10
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep (1998) 12.78
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 10.43
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 9.17
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science (2003) 7.91
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 6.31
Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med (1995) 5.55
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 5.23
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med (2000) 4.98
Epidemiology of hepatitis C. Hepatology (1997) 4.90
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol (1998) 4.52
Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol (2001) 4.48
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods (2002) 4.48
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology (2003) 4.21
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
Hepatitis C: global prevalence. Wkly Epidemiol Rec (1997) 3.95
Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature (1998) 3.78
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.68
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Hepatic T cells and liver tolerance. Nat Rev Immunol (2003) 3.51
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol (1997) 3.46
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol (1992) 3.13
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis (2000) 3.01
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis (2000) 2.98
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
Epidemiology of hepatitis C in the West. Semin Liver Dis (1995) 2.77
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest (1996) 2.65
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 2.49
Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol (1999) 2.44
Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol (1995) 2.34
Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology (2004) 2.16
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol (1998) 1.92
Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol (2002) 1.81
An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol (1994) 1.68
Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest (2004) 1.58
Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol (1993) 1.57
Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single-and double-stranded DNAs. J Clin Microbiol (1998) 1.53
Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology (1998) 1.47
Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology (1997) 1.40
Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV. J Virol (2001) 1.34
Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol (2004) 1.26
Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. Immunol Rev (2000) 1.15
Three new cytotoxic T cell epitopes identified within the hepatitis C virus nucleoprotein. J Gen Virol (1996) 1.01
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol (2005) 7.40
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A (2005) 6.64
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
The immune epitope database 2.0. Nucleic Acids Res (2009) 6.07
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Protection against persistence of hepatitis C. Lancet (2002) 5.94
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest (2002) 5.42
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol (2003) 4.64
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol (2006) 4.52
Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A (2009) 4.47
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One (2007) 3.99
Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol (2005) 3.93
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol (2006) 3.73
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 3.72
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol (2008) 3.71
NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59
HLA class I supertypes: a revised and updated classification. BMC Immunol (2008) 3.47
Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med (2004) 3.43
Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing. Proc Natl Acad Sci U S A (2013) 3.35
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
The design and implementation of the immune epitope database and analysis resource. Immunogenetics (2005) 3.00
Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics (2005) 2.99
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics (2005) 2.91
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med (2013) 2.84
Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol (2007) 2.71
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A (2007) 2.67
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics (2010) 2.53
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
Mechanism of induction and suppression of antiviral immunity directed by virus-derived small RNAs in Drosophila. Cell Host Microbe (2008) 2.48
Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol (2008) 2.48
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A (2008) 2.43
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology (2012) 2.36
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 2.32
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics (2008) 2.26